{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T02:53:26Z","timestamp":1789872806125,"version":"4.0.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.lungcan.2015.06.014","type":"journal-article","created":{"date-parts":[[2015,6,22]],"date-time":"2015-06-22T23:03:56Z","timestamp":1435014236000},"page":"306-310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy"],"prefix":"10.1016","volume":"89","clinical-trial-number":[{"clinical-trial-number":"nct01566019","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1968-652X","authenticated-orcid":false,"given":"M.","family":"Kossai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0872-2983","authenticated-orcid":false,"given":"B.","family":"Duchemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Boutros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Caramella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hollebecque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Angevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gazzah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bahleda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Ileana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Massard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Vielh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2015.06.014_bib0205","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.1990.8.8.1419","article-title":"Chemotherapy of invasive thymoma","volume":"8","author":"Fornasiero","year":"1990","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2015.06.014_bib0210","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejcts.2009.05.038","article-title":"Thymoma and thymic carcinoma","volume":"37","author":"Venuta","year":"2010","journal-title":"Eur. J. Cardio-Thorac. Surg. Off. J. Eur. Assoc. Cardio-Thorac. Surg."},{"key":"10.1016\/j.lungcan.2015.06.014_bib0215","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1378\/chest.128.4.2893","article-title":"Tumors of the mediastinum","volume":"128","author":"Duwe","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.lungcan.2015.06.014_bib0220","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1002\/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R","article-title":"Follow-up study of thymomas with special reference to their clinical stages","volume":"48","author":"Masaoka","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2015.06.014_bib0225","first-page":"S1710","article-title":"The Masaoka-Koga stage classification for thymic malignancies: clarification and definition of terms","volume":"6","author":"Detterbeck","year":"2011","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"10.1016\/j.lungcan.2015.06.014_bib0230","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s11864-009-0084-6","article-title":"The World Health Organization (WHO) histologic classification of thymomas: a reanalysis","volume":"9","author":"Moran","year":"2008","journal-title":"Curr. Treat Options Oncol."},{"key":"10.1016\/j.lungcan.2015.06.014_bib0235","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0003-4975(03)00555-1","article-title":"Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan","volume":"76","author":"Kondo","year":"2003","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.lungcan.2015.06.014_bib0240","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/1097-0142(19910701)68:1<30::AID-CNCR2820680106>3.0.CO;2-4","article-title":"Chemotherapy for invasive thymoma. A 13-year experience","volume":"68","author":"Fornasiero","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2015.06.014_bib0245","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0022-5223(03)00798-0","article-title":"Thymoma: a clinicopathologic study based on the new World Health Organization classification","volume":"126","author":"Nakagawa","year":"2003","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.lungcan.2015.06.014_bib0250","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"Lemma","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2015.06.014_bib0255","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1002\/1097-0142(20010601)91:11<2010::AID-CNCR1226>3.0.CO;2-2","article-title":"Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma","volume":"91","author":"Loehrer","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2015.06.014_bib0260","first-page":"73","article-title":"Multidisciplinary treatment for advanced invasive thymoma with cisplatin, doxorubicin, and methylprednisolone","volume":"2","author":"Yokoi","year":"2007","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"10.1016\/j.lungcan.2015.06.014_bib0265","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.lungcan.2009.03.031","article-title":"Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma","volume":"67","author":"Igawa","year":"2010","journal-title":"Lung Cancer Amst. Neth."},{"key":"10.1016\/j.lungcan.2015.06.014_bib0270","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s12032-009-9223-y","article-title":"Salvage chemotherapy with amrubicin and platinum for relapsed thymic carcinoma: experience in six cases","volume":"27","author":"Koizumi","year":"2010","journal-title":"Med. Oncol. Northwood Lond. Engl."},{"key":"10.1016\/j.lungcan.2015.06.014_bib0275","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/01.coc.0000227481.36109.e7","article-title":"Systemic treatment of malignant thymoma: a decade experience at a single institution","volume":"29","author":"Giaccone","year":"2006","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2015.06.014_bib0280","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.hoc.2008.03.007","article-title":"Molecular pathology of thymic epithelial neoplasms","volume":"22","author":"Kuhn","year":"2008","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.lungcan.2015.06.014_bib0285","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1158\/1078-0432.CCR-09-0644","article-title":"Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas","volume":"15","author":"Girard","year":"2009","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.lungcan.2015.06.014_bib0290","first-page":"S286","article-title":"Thymoma and thymic carcinoma: molecular pathology and targeted therapy","volume":"5","author":"Str\u00f6bel","year":"2010","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"10.1016\/j.lungcan.2015.06.014_bib0295","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1067\/mtc.2002.124389","article-title":"Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors","volume":"124","author":"Tomita","year":"2002","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.lungcan.2015.06.014_bib0300","first-page":"3708","article-title":"Correlating genetic aberrations with World Health Organization-defined histology and stage across the spectrum of thymomas","volume":"63","author":"Inoue","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2015.06.014_bib0305","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1002\/cncr.25367","article-title":"IGF-1R and p-AKT expression in 132 resected thymomas and thymic carcinomas","volume":"116","author":"Zucali","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2015.06.014_bib0310","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s11748-012-0160-x","article-title":"Immunohistochemical analysis of thymic carcinoma focusing on the possibility of molecular targeted and hormonal therapies","volume":"60","author":"Omatsu","year":"2012","journal-title":"Gen. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.lungcan.2015.06.014_bib0315","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1158\/1078-0432.CCR-11-1918","article-title":"Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors","volume":"18","author":"Isambert","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2015.06.014_bib0320","first-page":"2512","article-title":"Molecular screening for cancer treatment optimization (MOSCATO 01): a prospective molecular triage trial\u2013interim results","volume":"31","author":"Hollebecque","year":"2013","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1016\/j.lungcan.2015.06.014_bib0325","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrclinonc.2010.21","article-title":"mTOR signaling and drug development in cancer","volume":"7","author":"Dancey","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2015.06.014_bib0330","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","article-title":"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma","volume":"22","author":"Atkins","year":"2004","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2015.06.014_bib0335","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2015.06.014_bib0340","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2015.06.014_bib0345","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1002\/cncr.24280","article-title":"A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer","volume":"115","author":"Amato","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2015.06.014_bib0350","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5306\/wjco.v3.i7.111","article-title":"Everolimus plus long-acting somatostatin analogs in thymic epithelial malignancies","volume":"3","author":"Palmieri","year":"2012","journal-title":"World J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2015.06.014_bib0355","doi-asserted-by":"crossref","first-page":"890","DOI":"10.18632\/oncotarget.1015","article-title":"Thymoma patients treated in a phase I clinic at MD anderson cancer center: responses to mTOR inhibitors and molecular analyses","volume":"4","author":"Wheler","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2015.06.014_bib0360","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1158\/0008-5472.CAN-10-2700","article-title":"E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models","volume":"71","author":"Bello","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2015.06.014_bib0365","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1517\/13543780903213697","article-title":"AVE8062: a new combretastatin derivative vascular disrupting agent","volume":"18","author":"Delmonte","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.lungcan.2015.06.014_bib0370","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/sj.leu.2402788","article-title":"Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4","volume":"17","author":"Broggini","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.lungcan.2015.06.014_bib0375","doi-asserted-by":"crossref","first-page":"4616","DOI":"10.3748\/wjg.v16.i36.4616","article-title":"Clinicopathological features of gastric glomus tumor","volume":"16","author":"Fang","year":"2010","journal-title":"World J. Gastroenterol. WJG"},{"key":"10.1016\/j.lungcan.2015.06.014_bib0380","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.aanat.2007.05.003","article-title":"Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus","volume":"190","author":"Cimpean","year":"2008","journal-title":"Ann. Anat. Anat. Anz. Off. Organ Anat. Ges."},{"key":"10.1016\/j.lungcan.2015.06.014_bib0385","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1007\/s005950170021","article-title":"Elevated serum vascular endothelial growth factor and basic fibroblast growth factor levels in patients with thymic epithelial neoplasms","volume":"31","author":"Sasaki","year":"2001","journal-title":"Surg. Today"},{"key":"10.1016\/j.lungcan.2015.06.014_bib0390","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12032-008-9100-0","article-title":"Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report","volume":"26","author":"Li","year":"2008","journal-title":"Med. Oncol."},{"key":"10.1016\/j.lungcan.2015.06.014_bib0395","unstructured":"Thomas A, Rajan A, Berman A, Scepura B, Brzezniak C, Carter C, et al. Clinical activity of sunitinib in patients with thymic carcinoma. Journal of Thoracic Oncology. 15th WCLC abstracts. 2013;8 supplement 2;S268-69."},{"key":"10.1016\/j.lungcan.2015.06.014_bib0400","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1007\/s10637-011-9774-6","article-title":"Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies","volume":"30","author":"Weiss","year":"2012","journal-title":"Invest. New Drugs"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500215002998?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500215002998?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T11:26:52Z","timestamp":1537529212000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500215002998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0169500215002998"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2015.06.014","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2015.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}